Analysts Conflicted on These Healthcare Names: Regeneron (REGN) and AnaptysBio Inc (ANAB)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regeneron (REGN) and AnaptysBio Inc (ANAB).

Regeneron (REGN)

In a report released yesterday, Alethia Young from Cantor Fitzgerald reiterated a Hold rating on Regeneron, with a price target of $441. The company’s shares closed on Friday at $356.66.

Young noted:

“: We reiterate our Neutral rating and $441 12-month PT on REGN shares. We view the quarter’s updates as incremental, with commentary on Eylea market growth and, most notably, on Dupixent commercial and clinical potential. REGN sounds confident about Eylea stability, which we think was positively reflected in this quarter’s earnings. We model 4Q US Eylea sales of $1.03B (+1% QoQ). We have increased our 4Q non-GAAP SG&A spend to $383M (18%), based on further investment in marketing related to launches like asthma. Our non-GAAP 4Q tax rate is now 4% and our 4QE EPS is $5.81/sh.”

According to TipRanks.com, Young is a 4-star analyst with an average return of 3.7% and a 46.3% success rate. Young covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Puma Biotechnology, and Intercept Pharma.

Regeneron has an analyst consensus of Hold, with a price target consensus of $419.75, representing a 17.7% upside. In a report issued on October 29, Morgan Stanley also maintained a Hold rating on the stock.

.

See today’s analyst top recommended stocks >>

AnaptysBio Inc (ANAB)

Stifel Nicolaus analyst Derek Archila maintained a Buy rating on AnaptysBio Inc yesterday and set a price target of $127. The company’s shares closed on Friday at $72.33, close to its 52-week low of $66.28.

Archila said:

“We adjust our model accordingly. While we continue to like the stock at these levels, we do recognize the lack of meaningful catalysts in the <6 month timeframe may keep more event-driven investors on the sidelines in the near term but, we do believe shares could start working as we get closer to important clinical readouts for etokimab in atopic dermatitis and chronic rhinosinusitis, both expected in the 2H19. Further, results from its IL-36R antagonist, ANB019, for generalized pustular psoriasis (GPP) are now expected in mid-2019 (previously had been expected in early 2019), could also serve as a catalyst. Ultimately, we remain positive on ANAB shares over the next ~12 months and think etokimab's emerging profile could be very competitive relative to existing treatment options within blockbuster indications. We maintain our Buy rating and $127 target price."

According to TipRanks.com, Archila is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.5% and a 35.9% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Pacira Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AnaptysBio Inc with a $144.17 average price target, implying a 99.3% upside from current levels. In a report issued on November 9, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $140 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts